Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 10/20 | 0.55 |
| ▸ | GABRA2 | P47869 | 6/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 6/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | CACNB4 | O00305 | 1/20 | 0.38 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.38 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.38 |
| ▸ | CACNG3 | O60359 | 1/20 | 0.38 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.38 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.38 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.38 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.38 |
| ▸ | CACNG7 | P62955 | 1/20 | 0.38 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.38 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.38 |
| ▸ | CACNG1 | Q06432 | 1/20 | 0.38 |
| ▸ | CACNB2 | Q08289 | 1/20 | 0.38 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15569041 | 0.87 | CACNA1B (0.53) | CACNA1BPTGS1PTGS2KCNH2CACNB4 | |
| SCHEMBL15772780 | 0.85 | CACNA1B (0.63) | CACNA1BKCNH2CACNB4CACNA1ACACNA1G | |
| SCHEMBL15771869 | 0.78 | CACNA1B (0.66) | CACNA1BKCNH2CACNB4CACNA1ACACNA1G | |
| SCHEMBL15568580 | 0.77 | CACNA1B (0.74) | CACNA1BKCNH2CACNB4CACNA1ACACNA1G | |
| SCHEMBL15772506 | 0.75 | CACNA1B (0.76) | CACNA1BKCNH2CACNB4CACNA1ACACNA1G | |
| SCHEMBL15773048 | 0.72 | CACNA1B (0.72) | CACNA1BKCNH2CACNB4CACNA1ACACNA1G | |
| SCHEMBL15568397 | 0.71 | CACNA1B (1.00) | CACNA1BKCNH2CACNB4CACNA1ACACNA1G | |
| SCHEMBL15568981 | 0.71 | CACNA1B (0.68) | CACNA1BKCNH2CACNB4CACNA1ACACNA1G | |
| SCHEMBL9526822 | 0.63 | GABRA2 (0.46) | GABRA2GABRB2GABRPGABRDGABRA1 | |
| SCHEMBL2598511 | 0.63 | L3MBTL1 (0.51) | CACNA1BPTGS1PTGS2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2885293-B1 | SUBSTITUTED PYRAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS | JANSSEN PHARMACEUTICA NV (BE) | 2016-07-27 | — | — | EP | claimed |
| EP-2885293-A1 | SUBSTITUTED PYRAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS | Janssen Pharmaceutica, N.V. (BE) | 2015-06-24 | — | — | EP | claimed |
| US-8901314-B2 | Substituted pyrazoles as N-type calcium channel blockers | JANSSEN PHARMACEUTICA NV (BE) | 2014-12-02 | — | — | US | claimed |
| US-20140163031-A1 | SUBSTITUTED PYRAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS | JANSSEN PHARMACEUTICA NV (BE) | 2014-06-12 | — | — | US | claimed |
| WO-2014028803-A1 | SUBSTITUTED PYRAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS | JANSSEN PHARMACEUTICA NV (BE) | 2014-02-20 | — | — | WO | claimed |
| EP-2885293-B1 | SUBSTITUTED PYRAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS | JANSSEN PHARMACEUTICA NV (BE) | 2016-07-27 | — | — | EP | disclosed |
| US-8901314-B2 | Substituted pyrazoles as N-type calcium channel blockers | JANSSEN PHARMACEUTICA NV (BE) | 2014-12-02 | — | — | US | disclosed |
| US-8901314-B2 | Substituted pyrazoles as N-type calcium channel blockers | JANSSEN PHARMACEUTICA NV (BE) | 2014-12-02 | — | — | US | disclosed |
| US-8901314-B2 | Substituted pyrazoles as N-type calcium channel blockers | JANSSEN PHARMACEUTICA NV (BE) | 2014-12-02 | — | — | US | disclosed |
| US-20140163031-A1 | SUBSTITUTED PYRAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS | JANSSEN PHARMACEUTICA NV (BE) | 2014-06-12 | — | — | US | disclosed |
| US-20140163031-A1 | SUBSTITUTED PYRAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS | JANSSEN PHARMACEUTICA NV (BE) | 2014-06-12 | — | — | US | disclosed |
| US-20140163031-A1 | SUBSTITUTED PYRAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS | JANSSEN PHARMACEUTICA NV (BE) | 2014-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140163031-A1 | SUBSTITUTED PYRAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS | CACNA1B, CACNA1E, CACNA1A | CACNA1B 1/4885GABRA2 797/4885GABRB2 436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.